ISPE's and PDA's Efforts are Different

Print this page         

ISPE and PDA have performed a detailed analysis of their two key initiatives ‘PQLI’ and ‘PCMO’ in order to ensure coordination and prevent unnecessary duplication. As a result, program leaders have determined that there is no significant overlap between the efforts of each organization. In those cases where overlap has been identified, agreement was reached to realign the scope and to work together to avoid any duplication of effort.

In summary, both ISPE and PDA have agreed that the PQLI and PCMO deliverables are:

  • Different
  • Complementary, and
  • Not in competition

With this in mind, we are determined to utilize the expertise of two organizations to find practical approaches for the changing pharmaceutical environment according to the new paradigm laid down in ICH Q8 (Q11), Q9 and Q10.


  • Click to go to My Communities of Practice
  • Click to go to My Affiliate or Chapter
  • Click to go to My Profile



Design Considerations for WFI Distillation Systems Part 2
Thursday, 28 Apr 2016 18.04

2016 Annual Meeting Honorary Chair, Joseph Jimenez, Novartis
Tuesday, 26 Apr 2016 12.04

Pharmaceutical Training to Meet Your Needs
Friday, 22 Apr 2016 16.04